Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK): valor razonable

Tesis ACCE

Takeda manufactures oncology, gastroenterology, and rare disease treatments, with major franchises in blood disorders (Adcetris, Ninlaro) and inflammatory bowel disease (Entyvio). The company has a structural advantage in rare disease through its 2018 Shire acquisition, which gave it a portfolio of niche, high-margin therapies with limited competition and pricing power. Revenue growth of 10.2% masks uneven execution: oncology faces biosimilar pressure on older drugs, but the rare disease segment is expanding faster and commands gross margins above 70%. The key near-term catalyst is the FDA decision on solanezumab for Alzheimer's disease, expected in late 2024, which could unlock a new indication for an existing asset and validate Takeda's neurology pivot. At a forward PE of 35.3 with negative ROE, the market is pricing in either significant margin compression or a need to prove that rare disease growth and pipeline productivity can offset patent cliffs in legacy oncology, neither of which is assured at current valuation.